公开(公告)号：US20240269235A1

公开(公告)日：2024-08-15

申请号：US18540652

申请日：2023-12-14

Applicant: Gilead Sciences, Inc.

Inventor： Manuel Baca ,  Sarah A. Gilmore ,  Magdeleine S. Hung ,  Hassan Javanbakht ,  Manu Kanwar ,  Shahzada Khan ,  Prasenjit K. Mukherjee ,  Mark R. Nagel ,  Giuseppe Papalia ,  Danny W. Tam ,  Majlinda K. Thomas

IPC: A61K38/20 ,  A61K38/00 ,  A61K39/395 ,  A61P31/20 ,  A61P35/00 ,  C07K14/55

CPC classification number: A61K38/2013 ,  A61K39/3955 ,  A61P31/20 ,  A61P35/00 ,  C07K14/55 ,  A61K38/00 ,  C07K2319/30

Abstract: Provided are serum half-life extended-IL-2 variant (IL-2v) heterodimers having reduced binding to the IL2Rα (CD25) subunit. In particular, Fc-IL-2v heterodimers are provided and methods for making and using, e.g. for enhancing an immune response, e.g. in the prevention and treatment of viral infections and cancer.

公开(公告)号：US20220125884A1

公开(公告)日：2022-04-28

申请号：US17506483

申请日：2021-10-20

Applicant: Gilead Sciences, Inc.

Inventor： Manuel Baca ,  Sarah A. Gilmore ,  Magdeleine S. Hung ,  Hassan Javanbakht ,  Manu Kanwar ,  Shahzada Khan ,  Prasenjit K. Mukherjee ,  Mark R. Nagel ,  Giuseppe Papalia ,  Danny W. Tam ,  Majlinda K. Thomas

IPC: A61K38/20 ,  C07K14/55 ,  A61P31/20 ,  A61P35/00 ,  A61K39/395

Abstract: Provided are serum half-life extended-IL-2 variant (IL-2v) heterodimers having reduced binding to the IL2Rα (CD25) subunit. In particular, Fc-IL-2v heterodimers are provided and methods for making and using, e.g. for enhancing an immune response, e.g. in the prevention and treatment of viral infections and cancer.

公开(公告)号：US11896648B2

公开(公告)日：2024-02-13

申请号：US17506483

申请日：2021-10-20

Applicant: Gilead Sciences, Inc.

Inventor： Manuel Baca ,  Sarah A. Gilmore ,  Hassan Javanbakht ,  Prasenjit K. Mukherjee

IPC: A61K38/20 ,  A61P35/00 ,  A61K39/395 ,  C07K14/55 ,  A61K38/00 ,  A61P31/20

CPC classification number: A61K38/2013 ,  A61K39/3955 ,  A61P31/20 ,  A61P35/00 ,  C07K14/55 ,  A61K38/00 ,  C07K2319/30

Abstract: Provided are serum half-life extended-IL-2 variant (IL-2v) heterodimers having reduced binding to the IL2Rα (CD25) subunit. In particular, Fc-IL-2v heterodimers are provided and methods for making and using, e.g. for enhancing an immune response, e.g. in the prevention and treatment of viral infections and cancer.